SEATTLE, WA, January 03, 2012 – Adaptive TCR Corporation, a leading provider of next generation sequencing assays for the adaptive immune system marketed under the brand name immunoSEQ, announced today it has changed its name to Adaptive Biotechnologies Corporation effective immediately.

The name change reflects the expanded capabilities of the company’s original immune profiling business as well as the translation of select research findings from the lab to the clinic.

“Replacing TCR with Biotechnologies better represents the full nature and potential of our products and services,” explained Chad Robins, CEO and president of the newly named corporation. “For example, immunoSEQ now offers B-cell receptor sequencing, and we are developing clinical applications for the diagnosis and prognosis of cancer. The name change is simply a natural evolution of our business.”

The growth of immunoSEQ
immunoSEQ was launched in 2010 as the first high-throughput sequencing assay to profile the complete repertoire of T-cells in patients with cancer, autoimmune disorders, and infectious diseases.

Over the past year, the capabilities of this proprietary and groundbreaking immune sequencing platform have been expanded to include B-cell receptor sequencing and additional T-cell loci. Sequencing assays for non-human primates, bovine, and swine are also under development.

Expanding into clinical applications
The growing body of immune profiling research that has been generated by hundreds of studies looking at the impact of the immune repertoire on clinical outcome have led to the development of several clinical applications, specifically in oncology.

These clinical applications include monitoring minimal residual disease in blood-based cancers, a more accurate laboratory measurement for immune reconstitution post transplantation, and a direct measurement of tumor infiltrating lymphocytes (TIL) as a prognostic indicator of ovarian cancer.

Further, Adaptive is developing threshold tests to stratify patients in clinical trials, as a predictive measure of response to therapeutics and vaccines.

“immunoSEQ is a rapidly growing platform technology that provides fertile ground to move next generation immune sequencing technology into the clinic,” commented Robins. “We are developing assays that use a patient’s immune profile to inform treatment decisions.”

Adaptive Biotechnologies is building a strong patent portfolio as these first-time discoveries are becoming increasingly defensible with accurate and replicable data.

The company intends to make these tools available to as many researchers and clinicians as possible to ensure that the status of a patient’s immune system is taken into consideration at the point-of-care.

“Only with this critical information about the immune microenvironment, can genetic testing of a tumor truly be tailored to the individual,” said Adaptive’s scientific founder Harlan Robins. “A comprehensive lens of the immune repertoire made available by immunoSEQ may be required for the true potential of personalized medicine to be achieved.”

All information about the company can now be found at its new web address:
www.adaptivebiotech.com.

About Adaptive Biotechnologies Corporation and immunoSEQ™
Adaptive Biotechnologies Corporation (http://www.adaptivebiotech.com), headquartered in Seattle, WA, is pioneering the field of genomic immunology. The company’s core competency is developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research community and the biopharmaceutical industry. Its flagship commercial product, immunoSEQ (http://www.immunoSEQ.com), uses a proprietary immune profiling assay to analyze T cells and B cells – critical components of the adaptive  immune system’s defense against disease – with unprecedented depth and specificity. Sequencing the variable region of these immune cells allows researchers to characterize the complete immune repertoire of a patient or group of patients in search of immunologic biomarkers. Fueled by discoveries from immunoSEQ, the company is currently developing a pipeline of clinical assays that are specific to cancer diagnosis and prognosis. All of Adaptive Biotechnologies’ assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface. immunoSEQ was launched in September 2010 and has a worldwide customer base.

SEATTLE, WA, October 17, 2011 – A new study published in The Journal of Immunological Methods demonstrates conclusively that immunoSEQ, Adaptive TCR Corporation’s breakthrough solution for immune profiling, provides a sensitive, reliable method for researchers to accurately evaluate overall T cell receptor repertoire diversity, search for specific clones of interest, and compare repertoires to each other.

The study, published in the journal’s October 10, 2011, issue, was conducted by a team of Adaptive scientists, led by company co-founder Harlan Robins, Ph.D., who is also a faculty member at the Fred Hutchinson Cancer Research Center.

“Our experiments illustrate the high degree of sensitivity and reproducibility of the immunoSEQ assay,” explained Dr. Robins. “For the first time, researchers now have a precise, accurate snapshot of what’s going on in the adaptive immune system at any given moment.”

Applications of the technology that will benefit greatly from the increase in sensitivity include monitoring post-transplant immune reconstitution, detection of minimal residual disease, and evaluating the efficacy of cancer immunotherapy treatments.

Details of the Study

The study tests the limits of detection of the immunoSEQ assay, using a strategy whereby T cell clones possessing well-characterized TCRB rearrangements are spiked into a complex background of T cells. The mixes are then sequenced using immunoSEQ’s high-throughput deep sequencing methodology, generating millions of sequence reads that enable researchers to profile the repertoire of TCRβ chains present in each sample. The fraction of sequence reads corresponding to the known spiked in clone is then compared to the expected fraction for a number of samples with clones present at varying levels.

The data suggest that this technique is able to accurately detect a particular clone present at a frequency as low as one cell in 100,000, which is a vast improvement in sensitivity over current methods for characterizing T cell receptor repertoires.

Additionally, the assay is accurate across four orders of magnitude and is, therefore, reliably quantitative whether a clone of interest is rare, or present at a high frequency in the sample.

Finally, the study has shown that the immunoSEQ assay is reproducible by describing results from several replicate experiments.

immunoSEQ: Cloud-Based Solution for Immune Profiling

immunoSEQ provides next-generation DNA sequencing assays for key T and B cell receptor genes, allowing researchers to view the cells of the adaptive immune system with unprecedented depth.

To manage the very large amount of data generated by an immunoSEQ assay, Adaptive developed the ImmunoSEQ Analyzer™, a bioinformatics software suite that provides researchers the essential tools to discover meaningful information. Together, the immunoSEQ assays and software reveals details of the immune system that were historically difficult or impossible to detect.

Chad Robins, CEO and President of Adaptive TCR, added, “Since the analysis part of the solution is cloud-based, meaning the data can be viewed and manipulated from any computer with Internet access, we’re able to offer this technology to researchers around the world.”

As the study highlights, these researchers now have a powerful new tool to aid in the understanding of adaptive immunity

The full text of the study can be found at the website for The Journal of Immunological Methods, click here for Abstract page.

Please note access to the full text of this article will depend on your personal or institutional entitlements.

About Adaptive TCR Corporation and immunoSEQ™

Adaptive TCR Corporation (www.adaptivetcr.com), based in Seattle, WA, is a pioneer in the field of genomic immunology. Its first commercial product, immunoSEQ, uses a proprietary immune profiling assay to analyze T cells and B cells – critical components of the adaptive immune system’s defense against disease – with greater depth and resolution than ever before. This breakthrough technology allows researchers to characterize the complete immune repertoire of a patient or group of patients in search of immunologic biomarkers. The assay is coupled with a state-of-the-art cloud-computing infrastructure that simplifies the interpretation of mass quantities of data in a user-friendly interface, accessible through any standard web browser. The immune profiling technology was invented by Adaptive TCR co-founders, Harlan Robins, Ph.D., and Chris Carlson, Ph.D. at the Fred Hutchinson Cancer Research Center. The company began commercial operations in 2009 under the leadership of Chad Robins, CEO.

For additional information, contact:
Cindy Desmarais, Ph.D.
206-659-0521
cdesmarais@adaptivetcr.com

SEATTLE, WA, September 29, 2011 – Adaptive TCR Corporation, a leading provider of online solutions for large scale immune system profiling under the brand name immunoSEQ, announced today several high profile additions to its Board of Directors, Corporate Advisory Board, and Scientific Advisory Board.

“These new board members will further diversify the wealth of experience and deep industry knowledge that our directors already bring to this company,” said Chad Robins, CEO and President of Adaptive TCR Corporation. “Each individual is a respected and an accomplished leader in their fields, and I look forward to working with all the directors as we continue to grow and provide ground-breaking technology to the research community.”

Board of Directors
Joining the Board of Directors will be Dr. Lee Huntsman, President Emeritus of the University of Washington and Chairman of the Washington State Life Sciences Discovery Fund, and Dr. Arnold Levine, Systems Biology Professor at the Institute for Advanced Study in Princeton, who discovered the p53 tumor suppressor protein.

“Lee brings a broad-based perspective on management, and Arnie, who has been with Adaptive since early on as a scientific advisor, will continue to offer his insight and wide-ranging expertise,” added Robins.

Huntsman and Levine join current Adaptive board members Dr. Andris Zoltners, Founder and Chairman of ZS Associates, Craig Weissman, former Chief Technology Officer at Salesforce.com, and Robins.

Corporate Advisory Board
Dr. Carol Gallagher, former President and CEO of Calistoga Pharmaceuticals, and Stewart Parker, the CEO of the Infectious Disease Research Institute in Seattle, WA., join the Corporate Advisory Board.

“Carol has challenged us to think big and is an insider in the biopharmaceutical world, while Stewart brings an understanding of strong management and is an excellent judge of character,” described Robins.

Gallagher and Parker join board members Graham C. Allen, President and CEO of Sloan Valve Company, Matt Kahn, Executive Vice President at LRP Publications, Peter Keane, Senior Vice President at Pulte Homes, Dr. Richard Mitchell, Director of Business Development at the Fred Hutchinson Cancer Research Center, and Josh Rosen, Partner at Freshford Capital Management.

Scientific Advisory Board
Dr. Cassian Yee, a member of the Fred Hutchinson Cancer Research Center, where he focuses primarily on cancer immunotherapy, joins the Scientific Advisory Board.

“We’re extremely fortunate to have someone like Cassian on the board,” said Robins. “He’s a true leader in the field of cancer immunotherapy, which is a key target for Adaptive.”

Yee joins board members Dr. Gerald T. Nepom, Director at the Benaroya Research Institute, Dr. Jay Shendure, Assistant Professor of Genome Sciences at the University of Washington, and Dr. Edus Houston Warren, Associate Professor in the Department of Medicine at the University of Washington.

About Adaptive TCR Corporation and immunoSEQ™
Adaptive TCR Corporation, headquartered in Seattle, WA, develops, commercializes and supports online solutions for large scale immune system profiling. Adaptive TCR’s proprietary technologies were developed at the Fred Hutchinson Cancer Research Center by co-founders Harlan Robins, PhD and Chris Carlson, PhD. The technologies include a DNA amplification chemistry that can generate many millions of T cell receptor sequences from a single DNA sample, and a bioinformatics software suite designed specifically to manage the large amounts of data resulting from a typical assay. These technologies are marketed for life science research applications under the brand name immunoSEQ and immunoSEQ Analyzer™. The company began commercial operations in 2009 under the leadership of Chad Robins, CEO.

Dr. Walter J. Urba of the Providence Cancer Center in Portland, Oregon, and editorialist at The New England Journal of Medicine called the findings “pretty remarkable.”

The Role of ImmunoSEQ

To help analyze their data and validate their results, the scientists used a revolutionary immune profiling assay called immunoSEQ.

Dr. Michael Kalos, one of the lead researchers and Adjunct Associate Professor of Pathology and Laboratory Medicine, explained, “The immunoSEQ service has fundamentally changed how my lab does analysis of our clinical trials. I’m very impressed with its ability to provide such a granular view of T cells and B cells present in samples.”

Using ImmunoSEQ’s high-throughput immune profiling assay, Dr. Kalos and his colleagues used the technology to survey the entire IgH repertoire in two patients, confirming the results obtained using traditional but lower resolution methods to study the B cell receptor repertoire in these patients.

The cancer clone was readily detected in these patients both before treatment and after the preinfusion conditioning regimen, at frequencies greater than 90%. The high sensitivity of the ImmunoSEQ assay was able to detect the early stages of normal B cell proliferation at 176 days after infusion in one patient, showing a diverse repertoire consistent with normal reconstitution.

Using ImmunoSEQ, the percentage of the overall B cell repertoire that consists of the cancer clone as opposed to normal healthy cells can be evaluated at regular time points with a high degree of precision.

Acknowledging immunoSEQ and the immunoSEQ Team

In the published report, the research team, which also included renowned scientist Dr. Carl June, Director of Translational Research at the Abramson Cancer Center at the University of Pennsylvania, specifically thanked members of the immunoSEQ team and cited the importance of the technology in their work:

“We are grateful to C. Desmarais and H. Robins at Adaptive TCR for their excellent assistance with IgH immune profiling, which was performed as a service by ImmunoSEQ. Additionally, ImmunoSEQ provided a cloud-based suite of computational analysis tools (ImmunoSEQ Analyzer) that we used for data interpretation.”

The study reports the results from 3 patients with chronic lymphocytic leukemia who had relapsed after receiving chemotherapy. The first and second leukemia patient appear cancer-free at one year after treatment. The condition of the third patient has improved but some evidence of cancer is still detectable. The scientists used a novel method to introduce new genes into patients’ T cells, adding an additional signaling mechanism to instruct the patient’s T cells to hunt and destroy their cancer cells.

While the size of the study was small, and Dr. Urba adds a note of caution, “It’s just three patients,” the potential for a long-term cure is promising.

And for immunoSEQ and its role in the research, Dr. Kalos offers, “I recommend it all the time to my colleagues.”

The published reports can be found here:

The New England Journal of Medicine

Science Translational Medicine

A brief listing of the news articles covering the reports:

New York Times
MSNBC
ABC News
NY Daily News
International Business Times
The Vancouver Sun

About Adaptive TCR Corporation and immunoSEQ™
Adaptive TCR Corporation, headquartered in Seattle, WA, is pioneering the field of genomic immunology. Adaptive develops, commercializes and supports online solutions for large-scale immune system profiling and is leveraging their technology for clinical applications in autoimmune diseases and cancer immunotherapeutics. Adaptive TCR’s proprietary technologies were developed at the Fred Hutchinson Cancer Research Center by co-founders Harlan Robins, PhD and Chris Carlson, PhD. The technologies include a DNA amplification chemistry that can generate many millions of T and B cell receptor sequences from a single DNA sample, and a bioinformatics software suite designed specifically to manage the large amounts of data resulting from a typical assay. These technologies are marketed for life science research applications under the brand name immunoSEQ and immunoSEQ Analyzer™. The company began commercial operations in 2009 under the leadership of Chad Robins, CEO.

“The infusion of new capital will enable Adaptive to continue growth of the ImmunoSEQ profiling service and invest in clinical applications in the oncology, autoimmune, and vaccine fields,” explained Chad Robins, CEO and President of Adaptive TCR Corporation.

Adaptive’s commercial product, immunoSEQ, uses a proprietary breakthrough immune profiling assay to analyze T cells and B cells – critical components of the adaptive immune system’s defense against disease – with greater depth and resolution than ever before. This allows researchers to characterize the complete immune repertoire of a patient or group of patients in search of immunologic biomarkers. The assay is coupled with a state-of-the-art cloud-computing infrastructure that simplifies the interpretation of mass quantities of data in a user-friendly interface, accessible through any standard web browser.

Since opening for business in March 2010, Adaptive has grown quickly, assembling an impressive roster of early adopters in the biomedical community and has gained rapid acceptance among academic institutions. It’s currently signing up new customers at the rate of almost one per day.

The immunoSEQ platform is also beginning to penetrate the biotech and pharma communities who view the technology as a method, among other uses, to stratify patient populations in clinical trials. For example, companies can use the ImmunoSEQ assay in trials as a means to potentially identify or predict responders vs. non-responders to a therapeutic or vaccine, thereby reducing the risk of failure in clinical trials.

The immune profiling technology was invented by Adaptive TCR co-founders, Harlan Robins, Ph.D., and Chris Carlson, Ph.D. at the Fred Hutchinson Cancer Research Center.

For more information, please visit: www.immunoseq.com

About Adaptive TCR Corporation and immunoSEQ™
Adaptive TCR Corporation, headquartered in Seattle, WA, is pioneering the field of genomic immunology. Adaptive develops, commercializes and supports online solutions for large-scale immune system profiling and is leveraging their technology for clinical applications in autoimmune diseases and cancer immunotherapeutics. Adaptive TCR’s proprietary technologies were developed at the Fred Hutchinson Cancer Research Center by co-founders Harlan Robins, PhD and Chris Carlson, PhD. The technologies include a DNA amplification chemistry that can generate many millions of T and B cell receptor sequences from a single DNA sample, and a bioinformatics software suite designed specifically to manage the large amounts of data resulting from a typical assay. These technologies are marketed for life science research applications under the brand name immunoSEQ and immunoSEQ Analyzer™. The company began commercial operations in 2009 under the leadership of Chad Robins, CEO.

SEATTLE, WA, May 9, 2011 – Adaptive TCR Corporation, a leading provider of online solutions for large scale immune system profiling under the brand name immunoSEQ, has named Julie Rubinstein as its new Vice President of Business Development, Oncology.

In her new role, Ms. Rubinstein will be in charge of managing and increasing pharmaceutical companies’ adoption of immunoSEQ in clinical trials in the Oncology field and developing strategic relationships for clinical applications of the technology.

“We’re thrilled to have Julie on board,” expressed Chad Robins, CEO and President of Adaptive TCR Corporation. “The breadth of her experience in oncology commercial development will help take Adaptive to the next level as we look to leverage the ImmunoSEQ platform into clinical applications.”

Prior to joining Adaptive, Ms. Rubinstein spent eight years in the Worldwide Commercial Development Group at Pfizer Oncology. Most recently, she was the global lead for strategic communications and stakeholder relations for the entire portfolio of 20+ compounds.

A veteran in the healthcare field, Ms. Rubinstein has held various positions at Johnson & Johnson and Morgan Stanley’s Global Health Care Group. An undergraduate from Wharton, she earned her MBA from Harvard Business School.

Ms. Rubinstein is currently the Vice Chair of the Board of Directors for The Valerie Fund, a pediatric oncology organization that funds psychosocial services for children with cancer and blood disorders at eight centers in NJ and NY.

About Adaptive TCR Corporation and immunoSEQ™
Adaptive TCR Corporation, headquartered in Seattle, WA, develops, commercializes and supports online solutions for large scale immune system profiling. Adaptive TCR’s proprietary technologies were developed at the Fred Hutchinson Cancer Research Center by co-founders Harlan Robins, PhD and Chris Carlson, PhD. The technologies include a DNA amplification chemistry that can generate many millions of T cell receptor sequences from a single DNA sample, and a bioinformatics software suite designed specifically to manage the large amounts of data resulting from a typical assay. These technologies are marketed for life science research applications under the brand name immunoSEQ and immunoSEQ Analyzer™. The company began commercial operations in 2009 under the leadership of Chad Robins, CEO.

Seattle, WA – Adaptive TCR Technologies, a biotech firm based in Seattle, WA, announced today that it has received a total of $1,047,054 in Qualifying Therapeutic Discovery Program (QTDP) grants for five (5) distinct projects using its proprietary immune profiling assay (innumoSEQ) to advance scientific understanding and development of diagnostics and clinical measurements for several diseases and conditions.

Specifically, the Company was awarded the following 5 grants: 1.) Prediction of Anti-TNF Response in Patients with Crohn’s Disease, 2.) Development of a Pre-symptomatic Biomarker for Type 1 Diabetes, 3.) Prediction of Active Disease State in Crohn’s Disease, 4.) Identification of Immune System Signatures in Patients with Ovarian Cancer, and 5.) Immune System Profiling as a Measure of Vaccine Efficacy.

“We are extremely appreciative of the support and recognition for the utility of immunoSEQ assay to examine and advance our understanding of disorders of the immune system,” offers Chad Robins, CEO and Founder of Adaptive TCR. “Leveraging next-generation sequencing provides us with a tool to ask fundamental questions that were previously impossible without the advance in technology. We believe this will lead to a better quality of life for many people.”

About the QTDP

The QTDP grant program provides support for innovative projects that are determined by HHS to have reasonable potential to result in new therapies to treat areas of unmet medical need, treat chronic or acute diseases and conditions, or reduce the long-term growth of health care costs in the United States.

About Adaptive TCR Corporation

Adaptive TCR Corporation, headquartered in Seattle, WA, develops, commercializes and supports online solutions for large scale immune system profiling. Adaptive TCR’s proprietary technologies were developed at the Fred Hutchinson Cancer Research Center by co-founders Harlan Robins, PhD and Chris Carlson, PhD. The technologies include a DNA amplification chemistry that can generate many millions of T cell receptor sequences from a single DNA sample, and a bioinformatics software suite designed specifically to manage the large amounts of data resulting from a typical assay. These technologies are marketed for life science research applications under the brand name immunoSEQ™ and immunoSEQ Analyzer™. The company began commercial operations in 2009 under the leadership of Chad Robins, CEO.

“We are thrilled that Mr. Weissman has joined our Board,” offers Chad Robins, CEO and Founder of Adaptive TCR. “Adaptive is at the intersection of life science and technology as our immunoSEQ product utilizes the software as a service (SaaS) model. Our ability to leverage Craig’s expertise at the helm of the industry leader in cloud computing and SaaS provides an extraordinary opportunity to dominate immune profiling in the cloud.”

About Adaptive TCR Corporation

Adaptive TCR Corporation, headquartered in Seattle, WA, develops, commercializes and supports online solutions for large scale immune system profiling. Adaptive TCR’s proprietary technologies were developed at the Fred Hutchinson Cancer Research Center by co-founders Harlan Robins, PhD and Chris Carlson, PhD. The technologies include a DNA amplification chemistry that can generate many millions of T cell receptor sequences from a single DNA sample, and a bioinformatics software suite designed specifically to manage the large amounts of data resulting from a typical assay. These technologies are marketed for life science research applications under the brand name immunoSEQ™ and immunoSEQ Analyzer™. The company began commercial operations in 2009 under the leadership of Chad Robins, CEO.

The exciting finding of this report is that a small fraction of the tens of millions of T cell receptors in the human adaptive immune system are actually the same among different individuals.  This is a highly unexpected finding with very significant practical implications.  The results, the researchers say, could speed development of  new medical diagnostics and of drugs or immunotherapies to treat disease and infection.

The power of these researchers’ observation lies in the fact that the adaptive immune system is involved in the body’s response to virtually every disease and infection.  That makes the cells of the adaptive immune system (T cells) ideal tools to diagnose and potentially treat a broad range of ailments, from infections to organ transplants to autoimmune diseases like multiple slcerosis.  Finding the specific T cells that respond to any particular disease is a critical first step, and that’s just what immunoSEQ technology was designed for.

“The immunoSEQ system grew out of the needs of our own research programs,” noted Robins. “We had questions that just could not be answered with existing approaches, and we were fairly sure that if we were able to look at a large fraction of body’s T cell population, rather than just a tiny subset, we would be much better able to understand the way the immune system responds to disease.  We are very gratified that this is in fact the case.”

ImmunoSEQ provides next-generation DNA sequencing assays for key T cell receptor genes, allowing researchers to view the cells of the adaptive immune system with unprecedented depth.  To manage the very large amount of data generated by an immunoSEQ test, Adaptive TCR developed the ImmunoSEQ Analyzer^TM, a bioinformatics software suite the provides researchers the essential tools to discover meaningful information.  Together, the immunoSEQ assays and software can reveal details of the immune system that would otherwise be all but invisible.

For more coverage of this important publication, please visit the Adaptive TCR media page.

About Adaptive TCR Corporation

Adaptive TCR Corporation, headquartered in Seattle, WA, develops, commercializes and supports online solutions for very large scale immune system profiling. Adaptive TCR’s proprietary technologies were developed at the Fred Hutchinson Cancer Research Center by co-founders Harlan Robins, PhD and Chris Carlson, PhD. The technologies include a DNA amplification chemistry that can generate many millions of  T cell receptor sequences  from a single DNA sample, and a bioinformatics software suite designed specifically to manage the large amounts of data resulting from a typical assay. These technologies are marketed for life science research applications under the brand name immunoSEQ™ and immunoSEQ Analyzer™. The company began commercial operations in 2009 under the leadership of Chad Robins, CEO.

Adaptive TCR Corporation is dedicated to providing life science researchers with powerful and innovative tools that allow for a deeper understanding of fundamental questions in the immune system, and to furthering the development of important new diagnostic, monitoring and preventative applications.

For more information, please contact

Guy Page, PhD
VP Business Development
206-659-0691
gpage@adaptivetcr.com

Founding scientist Dr. Chris Carlson expands on the benefits, “Adaptive has lowered the cost of entry to allow scientific exploration by a much broader scientific audience that might not have a large grant base yet, including junior faculty and post doctorates.” CEO Chad Robins continues, “this offering significantly expands Adaptive’s client base by providing a tailored solution based on budget and scientific area of interest. A principal investigator can now do a significant experiment with a budget of a few thousand dollars”. While there remains a large target market desiring the maximum number of reads that Adaptive provides, there is a tremendous growth market in providing immune profiling services at a lower price point, Robins explains.

Adaptive has invented a sample preparation methodology that enables profiling of the adaptive immune system. The company provides a suite of software tools for Companies and researchers to analyze, interpret, and visualize sequencing data. The Company is dedicated to providing researchers an innovative sequencing technology to allow for a deeper understanding of fundamental questions in the immune system. The Company was founded by Harlan Robins, PhD, Chris Carlson, PhD, and Chad Robins in 2009. Drs. Robins and Carlson developed the patent pending biochemical methodology and proprietary software employed by the company at the Fred Hutchinson Cancer Research Center. Adaptive provides a fee-for-service business for researchers and clinicians, and is actively involved in research to determine diagnostic, monitoring and preventative applications utilizing its T Cell Receptor sequencing technology.

Download the PDF of the entire Press Release

For more information, contact:

Jessica Andriesen, VP Operations

Adaptive TCR Corporation

(206) 659-0067

Fax: (206) 659-0667

jandriesen@adaptivetcr.com

www.adaptivetcr.com